Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol vs Hydralazine for Severe Preeclampsia
NCT07572656Completed
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of labetalol and hydralazine in preeclampsia (2 arms). Primary endpoint: Treatment efficacy at 6 hours. Started May 2024; status: completed.
02
Drugs
labetalolhydralazine
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT07572656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572656.